Last updated: February 14, 2026
Overview
NDC 54092-0385 corresponds to a biologic drug used in the treatment of specific autoimmune conditions. The drug has gained regulatory approval in key markets, including the U.S. and Europe, and has become a standard treatment option for certain indications. Its market success depends on factors such as therapeutic efficacy, patent status, competitive landscape, and pricing policies.
Market Landscape
Therapeutic Indications
The drug is approved primarily for rheumatoid arthritis, psoriatic arthritis, and moderate to severe plaque psoriasis. The global demand in these segments has increased due to rising prevalence rates:
- Rheumatoid arthritis affects approximately 0.5-1% of the adult population worldwide.[1]
- Psoriasis affects 2-3% globally.[2]
- The drug’s efficacy and safety profile have solidified its position as a first-line biologic.
Market Size and Growth
The biologics market in autoimmune conditions is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2028.[3]
- The U.S. dominates with an estimated $20 billion market for biologics in autoimmune diseases in 2022.
- Europe follows, with a market size approaching $10 billion in 2022.[4]
- Asia-Pacific shows higher growth potential, driven by increasing healthcare access.
Competitive Landscape
Key competitors include other biological agents such as etanercept, adalimumab, and newer biosimilars. Biosimilars are entering markets rapidly, potentially reducing drug prices and affecting revenue streams.
- Biosimilar penetration is estimated to reduce biologic prices by 20-40% within 3-5 years of market entry.[5]
- Patent expiry for the marketed originator biologics is expected within 3-5 years, which will accelerate biosimilar competition.
Pricing Analysis
Current Pricing
In the U.S., list prices range from $5,000 to $7,000 per month, depending on dosage and indication.[6]
- The average wholesale price (AWP): approximately $6,000/month.
- Patient out-of-pocket costs vary based on insurance, typically $200-$800/month after insurance.
Pricing Trends
- The introduction of biosimilars could lower prices by 25-40% within the next 2-3 years.
- In Europe, the drug's price is negotiated at a national level, often leading to discounts between 20-35% relative to U.S. prices.
| Price Projections for the Next 5 Years |
Year |
Estimated U.S. Average Monthly Price |
Key Factors |
| 2023 |
$6,200 |
Stable pricing; biosimilar entry begins. |
| 2024 |
$5,600 |
Biosimilar competition increases; negotiations tighten. |
| 2025 |
$5,000 |
Price reductions accelerate; biosimilar market share climbs. |
| 2026 |
$4,700 |
Further biosimilar launches; cost-driven price declines. |
| 2027 |
$4,500 |
Settlement and contract negotiations influence pricing; biosimilars capture larger market share. |
Pricing assumptions are based on the typical biosimilar price discounts, manufacturer strategies, and payer negotiations.[7]
Revenue Projections
- Before biosimonical competition, annual revenues for the original biologic could surpass $3 billion globally.[8]
- Post-biosimilar entry, revenue declines are expected to range from 25-50% over five years.
- The drug’s market share will shift from 80+% in the original biologic to a mixed portfolio with biosimilars, influencing revenue streams significantly.
Regulatory and Policy Influences
- U.S. biosimilar approval pathways and patent litigations are critical; recent legislation encourages biosimilar uptake.[9]
- Price transparency initiatives and value-based contracting are increasingly adopted in the U.S. and Europe.[10]
- European nations tend to negotiate discounts, which reduces the drug’s official price but sustains access.
Key Takeaways
- The drug holds a strong market position in autoimmune therapeutics owing to efficacy and safety measures.
- Price expectations will decline by approximately 20-40% within three years due to biosimilar competition.
- Revenues are expected to decrease as biosimilar market share increases, but strategic pricing and market access negotiations could mitigate losses.
- The global biosimilars market will heavily influence both pricing and revenue, with notable impact in mature markets like the U.S. and Europe.
FAQs
1. When is biosimilar competition expected to impact this drug?
Biosimilar entries are projected within 3-5 years, with market penetration increasing significantly thereafter.
2. How does biosimilar adoption influence drug pricing?
Biosimilars typically lead to 25-40% price reductions through competitive pressure.
3. What markets are most lucrative for this drug?
The U.S. and Europe remain most lucrative due to high prevalence and established reimbursement systems.
4. Are there specific regulatory risks?
Yes. Patent disputes and delays in biosimilar approval can affect timelines and market share.
5. What role do payers play in this market?
Payors increasingly negotiate risk-based or value-based contracts, influencing pricing and formulary access.[11]
References
[1] Global Burden of Disease Study 2019. Lancet.
[2] World Psoriasis Atlas, 2016.
[3] Persistence Market Research, 2022.
[4] European Medicines Agency, 2022.
[5] IQVIA Biologics Report, 2022.
[6] Drug Pricing Data, GoodRx, 2022.
[7] Biosimilar Market Outlook, HIMSS Analytics, 2022.
[8] Evaluate Pharma, 2022.
[9] U.S. FDA Biosimilar Policy, 2022.
[10] European Commission Pharmaceutical Guidelines, 2022.
[11] HealthSparq Market Access Insights, 2022.
